Cannabinoids, Neural Synchrony, and Information Processing
- Registration Number
- NCT00708994
- Lead Sponsor
- Yale University
- Brief Summary
The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Men and women aged 18 and 55 years (extremes included) on the day of the first dosing.
- Exposed to cannabis at least once.
Exclusion Criteria
- Cannabis naïve
- Positive pregnancy screen during screening
- Hearing deficits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes THC THC * Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes. * Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes. * Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or "joint". Administered intravenously over 10 minutes.
- Primary Outcome Measures
Name Time Method EEG +30 Clinician Administered Dissociative Symptoms Scale, Positive and Negative Symptom Scale, Visual Analog Scale Baseline, +10, +80
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link THC-induced neural synchrony changes to psychosis onset in cannabis users?
How does Δ9-THC compare to antipsychotics like risperidone in modulating gamma-band EEG synchrony in early psychosis?
Which EEG biomarkers predict individual response to THC in patients with cannabis use disorder and psychotic symptoms?
What are the long-term adverse events of acute THC administration on neural synchrony in NCT00708994?
How do endocannabinoid receptor antagonists like rimonabant interact with THC effects on neural synchrony in psychosis models?
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸West Haven, Connecticut, United States
VA Connecticut Healthcare System🇺🇸West Haven, Connecticut, United States